12:00 AM
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GIC-1001: Phase IIa started

gIcare began a double-blind, placebo-controlled, dose-ranging, U.S. and Canadian Phase IIa trial to evaluate thrice-daily 250, 375 and 500 mg oral GIC-100 for 3 days and a tenth dose given...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >